We are live on ! Find out more
ZOM

Zomedica Corp.

Delisted

ZOM was delisted on the 4th of March, 2025.

7 hedge funds and large institutions have $126K invested in Zomedica Corp. in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less capital invested

Capital invested by funds: $141K → $126K (-$14.4K)

22% less funds holding

Funds holding: 97 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-2
Holders Change %
-22.22%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
2
Closed
3
Calls
Puts
Net Calls
Net Calls Change

ZOM Hedge Fund Activity: Q4 2025 in Review

7 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in Zomedica Corp. (ZOM) for Q4 2025, worth a combined $126K — down 10% from $141K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ZOM and 1 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was EverSource Wealth Advisors, opening a new position worth an estimated $1. The largest seller was Ancora Advisors, cutting an estimated $53K.

  • 7 institutional investors held Zomedica Corp. (ZOM) as of Q4 2025, down from 9 in Q3 2025.
  • Funds reported $126K of Zomedica Corp. stock for Q4 2025, down 10% quarter-over-quarter.
  • 1 fund opened new Zomedica Corp. positions in Q4 2025 and 3 closed out, a net change of -2 holders.
  • The largest Zomedica Corp. buyer in Q4 2025 was EverSource Wealth Advisors, an estimated $1 added.
  • The largest Zomedica Corp. seller in Q4 2025 was Ancora Advisors, an estimated $53K sold.

Based on aggregated 13F filings for Q4 2025.